ArticleNature immunology2018
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 377 papers.
0numbers the graph read from it
0cells of the map it votes in
377citing papers in PubMed
12.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
377 citing papers in PubMed, 544 citations in OpenAlex.
- Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer.Nature communications · 2025Trial
- In vivo immune cell engineering from bench to clinical reality.Pharmaceutical science advances · 2026Review
- Reprogramming tumor-associated macrophages in breast cancer: from myeloid plasticity and tumor-promoting programs to CAR-macrophage therapy.Journal of hematology & oncology · 2026Review
- Donor-targeted anti-HLA-A2 antibody shows nanogram-level efficacy in a novel GVHD mouse model.Blood advances · 2026Article
- Protocol for robust gene knockout and reliable validation in human cell lines using quad-guide RNA vectors.STAR protocols · 2026Article
- Research advances on CD47 in digestive system cancers: from molecular mechanisms to clinical translation.Molecular medicine (Cambridge, Mass.) · 2026Review
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Article
- High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma.Nature communications · 2026Article
- Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies.Smart molecules : open access · 2026Review
- Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability.AIDS (London, England) · 2026Article
- LMO7 Suppresses Tumor-Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- CCL19bioRxiv : the preprint server for biology · 2026Article
- Satellite microglia-like cells in human dorsal root ganglia and changes with diabetic neuropathy.bioRxiv : the preprint server for biology · 2026Article
- CXCL16-driven CD4Journal for immunotherapy of cancer · 2026Article
- SLC38A4 promotes Kupffer cell phagocytosis and suppresses tumor liver metastasis.Experimental & molecular medicine · 2026Article
- CD1d functions as a ligand for PIRA2 to drive macrophage activation in nonalcoholic fatty liver disease.Cell death & disease · 2026Article
- An integrative single-nucleus multiomic atlas of the human left ventricle identifies gene regulatory network dynamics across cardiac development, aging, and disease.Genome biology · 2026Article
- LILRB3 inhibition reverses immunosuppression in glioma: a nanoparticle-based therapeutic strategy.Journal of nanobiotechnology · 2026Article
- Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer.Science immunology · 2026Article
317 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 5 institutions in 2 countries.
Amira A BarkalInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Kipp WeiskopfInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Kevin S KaoInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Sydney R GordonInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Benyamin RosentalInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Ying Y YiuInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Benson M GeorgeInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Maxim MarkovicInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Nan G RingInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Jonathan M TsaiInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Kelly M McKennaInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Po Yi HoInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Robin Z ChengInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-7294-8907
James Y ChenInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Layla J BarkalDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA.ORCID http://orcid.org/0000-0002-4734-7197
Aaron M RingDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Irving L WeissmanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. irv@stanford.edu.ORCID http://orcid.org/0000-0002-9077-7467
Roy L MauteInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA. rmaute@stanford.edu.ORCID http://orcid.org/0000-0001-7501-3285
Stanford University · USCalifornia Institute for Regenerative Medicine · USBrigham and Women's Hospital · USUniversity of Wisconsin–Madison · USYale University · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8MLeveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MINTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3MMOLECULAR CHARACTERIZATION OF ACUTE MYELOID LEUKEMIAR01CA086017 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2000 to 2015
$5.5MGenes, cells, and pathways that regulate urochordate allogeneic stem cell competition and their mammalian homologuesR01GM100315 · NIGMS · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2012 to 2019
$2.8MProgram in Translational and Experimental HematologyT32HL120824 · NHLBI · STANFORD UNIVERSITY · PI MAJETI, RAVINDRA · 2014 to 2023
$2.4MTargeting the Major Histocompatibility Class I-LILRB1 signaling axis for cancer immunotherapy by macrophagesF30CA232472 · NCI · STANFORD UNIVERSITY · PI BARKAL, AMIRA · 2018 to 2020
$116kMolecular and Cellular Changes in the Peritoneal Surface Mesothelium during Adhesion FormationF30DK108561 · NIDDK · STANFORD UNIVERSITY · PI TSAI, JONATHAN MICHAEL · 2015 to 2018
$96kNCI NIH HHS F30 CA232472NCI NIH HHS R01 CA086017NCI NIH HHS T32 CA009302NHLBI NIH HHS T32 HL120824NIDDK NIH HHS F30 DK108561NIGMS NIH HHS R01 GM100315NIGMS NIH HHS T32 GM007365NIGMS NIH HHS T32 GM008692
Abstract
Exciting progress in the field of cancer immunotherapy has renewed the urgency of the need for basic studies of immunoregulation in both adaptive cell lineages and innate cell lineages. Here we found a central role for major histocompatibility complex (MHC) class I in controlling the phagocytic function of macrophages. Our results demonstrated that expression of the common MHC class I component β
Indexed as
AnimalsCell Line, TumorHistocompatibility Antigens Class IHumansImmunotherapyLeukocyte Immunoglobulin-like Receptor B1MacrophagesMice, Inbred BALB CMice, Inbred C57BLMice, Inbred NODMice, KnockoutMice, SCIDNeoplasmsNeoplasms, ExperimentalPhagocytosisHistocompatibility Antigens Class ILeukocyte Immunoglobulin-like Receptor B1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.